N-[(4-hydroxy-2-oxo-1-{[4'-(trifluoromethoxy)biphenyl-4-yl]methyl}-1,2,5,7-tetrahydrothieno[3,4-b]pyridin-3-yl)carbonyl]glycine | 1186091-42-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(4-hydroxy-2-oxo-1-{[4'-(trifluoromethoxy)biphenyl-4-yl]methyl}-1,2,5,7-tetrahydrothieno[3,4-b]pyridin-3-yl)carbonyl]glycine
• 英文别名: 2-[[4-Hydroxy-2-oxo-1-[[4-[4-(trifluoromethoxy)phenyl]phenyl]methyl]-5,7-dihydrothieno[3,4-b]pyridine-3-carbonyl]amino]acetic acid
• CAS: 1186091-42-8
• 化学式: C₂₄H₁₉F₃N₂O₆S
• 分子量: 520.486
• InChiKey: JPSALABSOHRMMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• TETRAHYDROTHIENO PYRIDINES
  申请人：Debenham John S.

  公开号：US20110009425A1

  公开（公告）日：2011-01-13

  The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

  本发明涉及四氢噻吩吡啶化合物，可用作HIF脯氨酸羟化酶抑制剂，用于治疗贫血和类似疾病。
• Inhibitors of HIF prolyl hydroxylase
  申请人：Cai Jiaqiang

  公开号：US10208060B2

  公开（公告）日：2019-02-19

  The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

  本发明涉及抑制 HIF 脯氨酰羟化酶的式 I 化合物或其药学上可接受的盐，它们用于增强红细胞生成素的内源性生成，治疗与红细胞生成素内源性生成减少有关的疾病，如贫血和类似疾病，以及包含此类化合物和药物载体的药物组合物。
• INHIBITORS OF HIF PROLYL HYDROXYLASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3197452B1

  公开（公告）日：2020-02-26
• US8445680B2
  申请人：——

  公开号：US8445680B2

  公开（公告）日：2013-05-21
• [EN] INHIBITORS OF HIF PROLYL HYDROXYLASE<br/>[FR] INHIBITEURS DE LA HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016049098A1

  公开（公告）日：2016-03-31

  The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.